BACKGROUND: Golimumab is a TNF-blocking agent indicated as a second-line therapy 
in ulcerative colitis.
PURPOSE: To research the effectiveness and safety of golimumab in patients with 
ulcerative colitis in clinical practice.
METHODS: Retrospective study of the effectiveness and safety of golimumab in 
patients with ulcerative colitis. All patients received golimumab 200 mg 
subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After 
the induction treatment, each patient received 50 mg sc. every 4 weeks in 
patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients 
with body weight greater than or equal to 80 kg.
RESULTS: Study of a group of 23 ulcerative colitis patients, 7 of whom were 
naive to any anti-TNF therapy, and 16 patients who had previously been treated 
with an anti-TNF agent other than golimumab (non-naive patients). The average 
treatment time with golimumab was 14.3 weeks. Globally, withdrawal of 
corticosteroids was observed in 74% of cases. Clinical response was observed in 
85.5% of patients who had not received biological treatment previously, and in 
patients who had previously received biological treatment the response rate was 
75%.
CONCLUSIONS: In this short study, golimumab seems to be an alternative treatment 
in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe 
therapy, given that there were no adverse effects in the patients studied.